Car T-Cell Therapy

An investigational chimeric antigen receptor T-cell therapy induced responses among patients with indolent lymphomas, according to topline data released by the agent’s manufacturer.

In this edition, CAR-T trial for leukemia paused after patient death; obesity may increase risk for blood cancer; new CAR T-cell therapies ‘waiting’ for patients with leukemia and more.

An international research collaboration has contributed new insights into how the gut microbiome contributes to the effectiveness of immunotherapy for cancer.

The FDA placed a clinical hold on a clinical program designed to investigate a chimeric antigen receptor T-cell therapy for treatment of relapsed or refractory multiple myeloma following a patient death.

Seattle Children’s Hospital has paused the phase 1 PLAT-08 trial of SC-DARIC33 after one patient treated with the investigational chimeric antigen receptor T-cell therapy died.

CHICAGO — Seventy-six percent of adults with relapsed or refractory B-cell acute lymphoblastic leukemia achieved complete response to treatment with obecabtagene autoleucel, interim results of the pivotal phase 2 FELIX trial showed.

Two teenagers with T-cell acute lymphoblastic leukemia achieved complete molecular remission after receiving a donor-based investigational chimeric antigen receptor T-cell therapy, phase 1 study results showed.

CHICAGO — Lisocabtagene maraleucel significantly improved complete remission rates among adults with relapsed or refractory chronic lymphocytic leukemia, results from the pivotal phase 2 TRANSCEND CLL 004 trial showed.

CHICAGO — Ciltacabtagene autoleucel significantly extended PFS compared with standard therapy for adults with relapsed and lenalidomide-refractory multiple myeloma, results from the randomized phase 3 CARTITUDE-4 study showed.